Sunstone has supported and funded companies that have been the originator of 20 life-changing products

Since the inception in 2007, Sunstone Life Science Ventures (Sunstone) has co-created, supported and funded life science companies that have been the originator of 20 life-changing products approved for the treatment or diagnosis of patients with cardiovascular, respiratory and infectious diseases, as well as cancer, neurological diseases, and those requiring surgical intervention.

While striving to provide a return on investment for our LPs, we are indeed most proud when we make a difference to patients in need of new and better treatment options. At the end of the day, we cannot think of any higher pursuit than helping patients suffering from difficult-to-treat diseases.

We saw a perfect example earlier this year when Chiesi Farmaceutici S.p.A. announced that the FDA had approved Lamzede® for the treatment of non-central nervous system manifestations of alpha-mannosidosis. Alpha-mannosidosis is an ultra-rare, progressive lysosomal storage disorder caused by a deficiency in the enzyme α-mannosidase. Lamzede® was developed by Sunstone portfolio company Zymenex A/S, which was acquired by Chiesi when Lamzede® was in the middle of a phase 3 study. Our kudos to Chiesi Farmaceutici, to Giacomo Chiesi heading the acquisition, to the Zymenex team and to Zymenex CEO @Jens Fogh.

Here is a list of all 20 approved products developed by Sunstone funded life science companies:

Zealand Pharma A/S

  • Lyxumia® (lixisenatide): A GLP-1 receptor agonist developed by Zealand Pharma and marketed by Sanofi
  • Zegalogue® (dasiglucagon): A glucagon receptor agonist for the treatment of severe hypoglycemia in people with diabetes. Marketed by Novo Nordisk.

Zymenex A/S

  • Lamzede®: A novel enzyme replacement for the treatment of non-central nervous system manifestations of alpha-mannosidosis. Marketed by Chiesi Farmaceutici S.p.A.

Nordic Vaccine A/S

  • Posintro™: A saponin based adjuvant technology now part of the Novavax Matrix-M™ technology and applied in the Novavax RSV and COVID-19 Vaccines

Arcoma AB

  • OMNERA 500A®: A digital X-ray System with New Intelligent Automation Features. Marketed by Canon Medical Systems.
  • Arcoma Precision i5®: A new high-end digital X-ray system.
  • Arcoma Intuition®: A versatile digital radiography system that combines outstanding image quality with clinical flexibility for a wide range of digital radiography applications.
  • Arcoma X-ray Cube®: A standalone self-supporting x-ray solution that enables quick installation of an X-ray system in, for example, a temporary hospital.

Acarix A/S

  • CADScor®System: An AI-powered acoustic diagnostic aid to diagnose coronary artery disease.

Evolva AG

  • Veri-te™ resveratrol: A compound that occurs naturally in red wine, grapes and other plants. Evolva’s resveratrol is a high-purity ingredient made via fermentation.

Euro Diagnostica A/S (now Svar Life Science AB):

  • iLite®: A cell-based reporter gene system including among others an Fc Effector Activity Bioassays (ADCC, ADCP) and T-Cell Activation Bioassays

Asante Inc.

  • Asante Snap™: An innovative insulin pump using standard insulin cartridges. Asante Snap™ is no longer marketed.

Chempaq A/S

  • Chempaq XBC eXpress™: Blood Counter & Analyzer. Chempaq XBC eXpress™ is no longer marketed.

Vivostat A/S

  • Vivostat® System: An operating room equipment that allows preparation of autologous Fibrin Sealant or Platelet Rich Fibrin (PRF)
  • Vivostat® Fibrin Sealant
  • Vivostat® PRF (Platelet Rich Fibrin): second generation platelet product Vivostat® PRF (Platelet Rich Fibrin)

JenaValve AG

  • Trilogy Heart Valve System: Approved for commercial use in the European Union for patients with Severe Aortic Regurgitation and Stenosis

Atonomics A/S (Now Qlife Holding AB)

  • The Egoo Device: A point of care device with the potential to measure several health-related parameters. Currently available for CRP

Egalet Inc (then Lyla, now Assertion)

  • AXAYDO: an abuse-deterrent oxycodone formulation for pain management.
What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases

Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and...

Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part...

Sunstone Life Science Ventures is looking for a Student Assistant

No longer accepting applications We are looking for a student to join our team for approximately 8 hours a week. As part of the team, you will play a pivotal role in the management of our deal flow, which lies in the order of 400-500 opportunities every year....

Sunstone announce new investment in immuno-oncology company STipe Therapeutics

Sunstone Life Science Ventures today announce it has invested in new portfolio company Stipe Therapeutics ApS (“STipe”), an immuno-oncology company dedicated to developing novel cancer therapeutics based on its first class drugs modulating the STING pathway.

Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia

Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia...

5 latest articles

Biotech startups in Scandinavia have 460 MEUR at hand – but burn is up – and runway the shortest in 3 years

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it's important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing,...

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?  For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has...

Why do VC’s not cut losses in time?

Why do VC’s not cut losses in time?  A clinical trial is a very expensive experiment for testing a hypothesis, while hoping for a positive outcome. However, if well designed, a negative outcome could increase the potential for a positive outcome in a subsequent trial....

Are some diseases associated with a higher risk of venture capital losses?

Are some diseases associated with a higher risk of venture capital losses?  Before summer we posted a study correlating venture capital losses in drug development with the magnitude of funding of clinical trials. We have used two approaches to find losses: 1)...

Do compromises in clinical trials cause Venture Capital losses?

Do compromises in clinical trials cause Venture Capital losses? In 2020 and 2021 Sunstone looked in depth at drug development venture-backed successes to find usable attributes and learn from the past. We have now turned the analysis up-side down and looked at the...

Who is in the driver’s seat of our industry?

A recent analysis from Pharma Intelligence | Informa 2021 highlights the current trends of pipeline products (top panel). We have subsequently surveyed Sunstone’s incoming deal flow for the same period and noted the correlation for the top 3 categories with oncology...